Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
11
HCWB Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
-5.28%
Day range:
$1.34 - $1.50
52-week range:
$1.34 - $41.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.23x
P/B ratio:
5.96x
Volume:
37.8K
Avg. volume:
111.9K
1-year change:
-91.51%
Market cap:
$2.7M
Revenue:
$2.6M
EPS (TTM):
-$13.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
$7M | -- | -100% | -- | $8.00 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
$1.42 | $8.00 | $2.7M | -- | $0.00 | 0% | 5.23x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.81 | $11.00 | $145.6M | 26.04x | $0.00 | 0% | 2.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
139.07% | -0.900 | 105.4% | 0.04x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
-$170.8K | -$3.3M | -382.71% | -626.36% | -21064.74% | -$3.2M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
HCW Biologics Inc. vs. Competitors
-
Which has Higher Returns HCWB or AIM?
AIM ImmunoTech has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of -10571.43%. HCW Biologics Inc.'s return on equity of -626.36% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About HCWB or AIM?
HCW Biologics Inc. has a consensus price target of $8.00, signalling upside risk potential of 463.38%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than HCW Biologics Inc., analysts believe AIM ImmunoTech is more attractive than HCW Biologics Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is HCWB or AIM More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock HCWB or AIM?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or AIM?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than AIM ImmunoTech quarterly revenues of $35K. HCW Biologics Inc.'s net income of -$4.6M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 5.23x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.5.23x -- $15.6K -$4.6M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns HCWB or CVM?
CEL-SCI Corp. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of --. HCW Biologics Inc.'s return on equity of -626.36% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About HCWB or CVM?
HCW Biologics Inc. has a consensus price target of $8.00, signalling upside risk potential of 463.38%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than HCW Biologics Inc., analysts believe CEL-SCI Corp. is more attractive than HCW Biologics Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is HCWB or CVM More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock HCWB or CVM?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or CVM?
HCW Biologics Inc. quarterly revenues are $15.6K, which are larger than CEL-SCI Corp. quarterly revenues of --. HCW Biologics Inc.'s net income of -$4.6M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 5.23x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.5.23x -- $15.6K -$4.6M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns HCWB or IGC?
IGC Pharma, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of -953.4%. HCW Biologics Inc.'s return on equity of -626.36% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About HCWB or IGC?
HCW Biologics Inc. has a consensus price target of $8.00, signalling upside risk potential of 463.38%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1192.1%. Given that IGC Pharma, Inc. has higher upside potential than HCW Biologics Inc., analysts believe IGC Pharma, Inc. is more attractive than HCW Biologics Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is HCWB or IGC More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock HCWB or IGC?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or IGC?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. HCW Biologics Inc.'s net income of -$4.6M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 5.23x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.5.23x -- $15.6K -$4.6M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns HCWB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of -255.85%. HCW Biologics Inc.'s return on equity of -626.36% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About HCWB or NBY?
HCW Biologics Inc. has a consensus price target of $8.00, signalling upside risk potential of 463.38%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that HCW Biologics Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe HCW Biologics Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is HCWB or NBY More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock HCWB or NBY?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or NBY?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. HCW Biologics Inc.'s net income of -$4.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 5.23x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.5.23x -- $15.6K -$4.6M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns HCWB or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of 13.19%. HCW Biologics Inc.'s return on equity of -626.36% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About HCWB or PLX?
HCW Biologics Inc. has a consensus price target of $8.00, signalling upside risk potential of 463.38%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 507.74%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than HCW Biologics Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than HCW Biologics Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is HCWB or PLX More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock HCWB or PLX?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or PLX?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. HCW Biologics Inc.'s net income of -$4.6M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 5.23x versus 2.30x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.5.23x -- $15.6K -$4.6M PLXProtalix Biotherapeutics, Inc.2.30x 26.04x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
